Awareness Raising

Horizon 2020- IDEA- FAST

EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these patients. 

Background

Read time: 2 mins

Out‐of‐pocket expenses of patients with inflammatory bowel disease

Out‐of‐pocket expenses of patients with inflammatory bowel disease: a comparison of patient‐reported outcomes across 12 European countries

October, 2022

There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, the study compared patient costs of IBDs between 12 European countries.

Read Study 

Read time: 1 min

Transition from pediatric to adult care

Transitioning through paediatric and into adult care is a critical time for patients and, if not carried out effectively and appropriately, can impact on education, mental health and patient outcomes. It has become clear that this is a major issue for patients, their carers and clinicians and that the transition process within and across Europe urgently needs reform.

Read time: 1 min

A Patient´s Guide to Nutrition in Inflammatory Bowel Disease

A Patient's Guide to Nutrition in Inflammatory Bowel Disease is written by Prof. Darija Vranešić Bender, clinical nutritionist  and Prof. Željko Krznarić, gastroenterologist and hepatologist, experts from University Hospital Zagreb, Croatia. The Guide is a result of long collaboration between the Referral center for IBD at the University Hospital Zagreb, Department of gastroenterology and hepatology and Unit of Clinical Nutrition, Croatian Society of Clinical Nutrition Croatian Medical Association and Croatian Crohn's and Colitis Patient Association.

Read time: 1 min

Paediatric inflammatory bowel disease

Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents

September, 2022

The study aims to find potential advanced treatment options for children with inflammatory bowel disease. A 2-day virtual meeting was held on April 14–15, 2021, for multi-stakeholders (clinical academics, patient community, pharmaceutical companies, and regulators) to discuss their perspectives on paediatric drug development for inflammatory bowel disease. 
 

Read time: 1 min